Access cutting-edge low-grade glioma treatment through this clinical trial at a research site in Little Rock. Study-provided care at no cost to qualified participants.
Access low-grade glioma specialists in Little Rock at no cost
This study follows strict safety protocols and ethical guidelines
All study-related low-grade glioma treatment provided free
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this low-grade glioma clinical trial in Little Rock, AR
If you're searching for low-grade glioma treatment options in Little Rock, AR, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Little Rock research site is actively enrolling participants for this clinical trial. You'll receive care from experienced low-grade glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.